APA (7th ed.) Citation

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2018). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. The American heart journal, 200, 83-89. https://doi.org/10.1016/j.ahj.2018.01.012

Chicago Style (17th ed.) Citation

Wiviott, Stephen D., et al. "The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial." The American Heart Journal 200 (2018): 83-89. https://doi.org/10.1016/j.ahj.2018.01.012.

MLA (9th ed.) Citation

Wiviott, Stephen D., et al. "The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial." The American Heart Journal, vol. 200, 2018, pp. 83-89, https://doi.org/10.1016/j.ahj.2018.01.012.